For many patients with lower-risk localized prostate cancer, forgoing or delaying definitive therapy through active surveillance (AS) can help them avoid significant side effects associated with surgery or radiation.
Related Articles
ArteraAI Achieves SOC 2 Type II Security Compliance Certification
ArteraAI x SOC 2 As part of our commitment to cybersecurity, we are proud to announce that ArteraAI is now SOC 2 Type II cert [...]
ArteraAI Predictive Models
ArteraAI is a leading precision medicine company developing AI tests to personalize cancer therapy. Download the pdf.